202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Filipe Pereira; Ervin Ascic; Fritiof Åkerström; Malavika Sreekumar Nair; André Rosa; Ilia Kurochkin; Olga Zimmermannova; Xavier Catena; Nadezhda Rotankova; Charlotte Veser; Michal Rudnik; Tommaso Ballocci; Tiffany Schärer; Xiaoli Huang; Emilie Renaud; Marta Velasco Santiago; Özcan Met; David Askmyr; Malin Lindstedt; Lennart Greiff; Irina Agarkova; Inge Marie Svane; Cristiana Pires; Fábio Rosa

doi:10.1016/j.exphem.2024.104584

202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Filipe Pereira, Ervin Ascic, Fritiof Åkerström, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannova, Xavier Catena, Nadezhda Rotankova, Charlotte Veser, Michal Rudnik, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, Lennart GreiffIrina Agarkova, Inge Marie Svane, Cristiana Pires, Fábio Rosa

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo..

Original language	English
Article number	2026
Journal	Experimental Hematology
Volume	137
Issue number	Suppl.
Pages (from-to)	104584
Number of pages	1
ISSN	0301-472X
DOIs	https://doi.org/10.1016/j.exphem.2024.104584
Publication status	Published - 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.exphem.2024.104584

OpenUrl availability

Full text

Cite this

Pereira, F., Ascic, E., Åkerström, F., Nair, M. S., Rosa, A., Kurochkin, I., Zimmermannova, O., Catena, X., Rotankova, N., Veser, C., Rudnik, M., Ballocci, T., Schärer, T., Huang, X., Renaud, E., Santiago, M. V., Met, Ö., Askmyr, D., Lindstedt, M., ... Rosa, F. (2024). 202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo. Experimental Hematology, 137(Suppl.), 104584. Article 2026. https://doi.org/10.1016/j.exphem.2024.104584

@article{4959539cceb4433888dcbde91e24b18a,

title = "202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo",

abstract = "Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo..",

author = "Filipe Pereira and Ervin Ascic and Fritiof {\AA}kerstr{\"o}m and Nair, {Malavika Sreekumar} and Andr{\'e} Rosa and Ilia Kurochkin and Olga Zimmermannova and Xavier Catena and Nadezhda Rotankova and Charlotte Veser and Michal Rudnik and Tommaso Ballocci and Tiffany Sch{\"a}rer and Xiaoli Huang and Emilie Renaud and Santiago, {Marta Velasco} and {\"O}zcan Met and David Askmyr and Malin Lindstedt and Lennart Greiff and Irina Agarkova and Svane, {Inge Marie} and Cristiana Pires and F{\'a}bio Rosa",

year = "2024",

doi = "10.1016/j.exphem.2024.104584",

language = "English",

volume = "137",

pages = "104584",

journal = "Experimental Hematology",

issn = "0301-472X",

publisher = "Elsevier",

number = "Suppl.",

}

Pereira, F, Ascic, E, Åkerström, F, Nair, MS, Rosa, A, Kurochkin, I, Zimmermannova, O, Catena, X, Rotankova, N, Veser, C, Rudnik, M, Ballocci, T, Schärer, T, Huang, X, Renaud, E, Santiago, MV, Met, Ö, Askmyr, D, Lindstedt, M, Greiff, L, Agarkova, I, Svane, IM, Pires, C & Rosa, F 2024, '202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo', Experimental Hematology, vol. 137, no. Suppl., 2026, pp. 104584. https://doi.org/10.1016/j.exphem.2024.104584

TY - JOUR

T1 - 202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

AU - Pereira, Filipe

AU - Ascic, Ervin

AU - Åkerström, Fritiof

AU - Nair, Malavika Sreekumar

AU - Rosa, André

AU - Kurochkin, Ilia

AU - Zimmermannova, Olga

AU - Catena, Xavier

AU - Rotankova, Nadezhda

AU - Veser, Charlotte

AU - Rudnik, Michal

AU - Ballocci, Tommaso

AU - Schärer, Tiffany

AU - Huang, Xiaoli

AU - Renaud, Emilie

AU - Santiago, Marta Velasco

AU - Met, Özcan

AU - Askmyr, David

AU - Lindstedt, Malin

AU - Greiff, Lennart

AU - Agarkova, Irina

AU - Svane, Inge Marie

AU - Pires, Cristiana

AU - Rosa, Fábio

PY - 2024

Y1 - 2024

N2 - Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo..

AB - Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo..

U2 - 10.1016/j.exphem.2024.104584

DO - 10.1016/j.exphem.2024.104584

M3 - Journal article

SN - 0301-472X

VL - 137

SP - 104584

JO - Experimental Hematology

JF - Experimental Hematology

IS - Suppl.

M1 - 2026

ER -

202A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Abstract

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this